$-0.02
(Market cap
$4 Mln
Recently Viewed
Clear AllMarket cap
$4 Mln
Revenue (TTM)
$0 Mln
P/E Ratio
--
P/B Ratio
1.9
Div. Yield
0 %
Today’s Range
52 Week Range
Liquidity
Net Profit (TTM)
$0 Mln
ROE
-2.5 %
ROCE
-- %
Industry P/E
--
EV/EBITDA
-3.1
Debt to Equity
0
Book Value
$0.6
EPS
$--
Face value
--
Shares outstanding
3,804,741
CFO
$-25.11 Mln
EBITDA
$-41.55 Mln
Net Profit
$-41.75 Mln
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Alzamend Neuro Inc (ALZN)
| -39.0 | -40.3 | -49.5 | 62.0 | -76.9 | -- | -- |
|
BSE Sensex
| -9.5 | 5.5 | -6.0 | -4.3 | 8.7 | 9.9 | 11.5 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2025
|
2024
|
2023
|
2022
|
|---|---|---|---|---|
|
Alzamend Neuro Inc (ALZN)
| 56.9 | -86.7 | -89.5 | -70.3 |
|
S&P Small-Cap 600
| 4.0 | 7.0 | 13.9 | -17.4 |
|
BSE Sensex
| 9.1 | 8.1 | 18.7 | 4.4 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Alzamend Neuro Inc (ALZN)
|
1.1 | 4.2 | 0.0 | -7.0 | -- | -187.1 | -- | 1.9 |
| 3.1 | 102.3 | 0.0 | -10.3 | -- | -64.5 | -- | 6.8 | |
| 5.9 | 81.5 | 57.9 | -2.3 | -4.1 | -57 | -- | 19.0 |
Alzamend Neuro, Inc., a clinical-stage biopharmaceutical company, focuses on developing various products for the treatment of neurodegenerative and psychiatric disorders. Its pipeline includes AL001, which delivers a therapeutic combination of... lithium, proline, and salicylate for the treatment of Alzheimer's, bi-polar disorder, post-traumatic stress disorder, major depressive disorder, other neurodegenerative diseases, and psychiatric disorders; and ALZN002, which uses a method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine to restore the ability of a patient's immunological system to combat Alzheimer's disease. Alzamend Neuro, Inc. was incorporated in 2016 and is headquartered in Atlanta, Georgia. Read more
CEO & Director
Mr. Stephan Jackman
Founder & Vice Chairman
Mr. Milton Charles Ault III
Headquarters
Atlanta, GA
Website
Our rating system has guided millions of investors in the past 20 years.
The share price of Alzamend Neuro Inc (ALZN) is $1.11 (NASDAQ) as of 24-Apr-2026 16:12 EDT. Alzamend Neuro Inc (ALZN) has given a return of -76.9% in the last 3 years.
Since, TTM earnings of Alzamend Neuro Inc (ALZN) is negative, P/E ratio is not available.
The P/B ratio of Alzamend Neuro Inc (ALZN) is 1.92 times as on 24-Apr-2026, a 58 discount to its peers’ median range of 4.57 times.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2025
|
--
|
--
|
|
2024
|
--
|
--
|
|
2023
|
--
|
--
|
|
2022
|
--
|
--
|
|
2021
|
--
|
--
|
The 52-week high and low of Alzamend Neuro Inc (ALZN) are Rs 8.22 and Rs 0.51 as of 26-Apr-2026.
Alzamend Neuro Inc (ALZN) has a market capitalisation of $ 4 Mln as on 24-Apr-2026. As per SEBI classification, it is a Small Cap company.
Before investing in Alzamend Neuro Inc (ALZN), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.